<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03701633</url>
  </required_header>
  <id_info>
    <org_study_id>0340-17-RMB</org_study_id>
    <nct_id>NCT03701633</nct_id>
  </id_info>
  <brief_title>Uterine Artery Doppler Changes Prior and After Breastfeeding</brief_title>
  <official_title>Postpartum Uterine Artery Doppler Changes Prior and After Breastfeeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to determine whether there are any differences in the UtA doppler measurements in
      postpartum women prior and right after breastfeeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is emerging evidence linking abnormal UtA Doppler indices in the postpartum period as a
      risk factor for developing future cardiovascular disorders. Thus far, no study considered the
      postpartum physiology itself as a possible confounder. If one wishes to draw conclusions
      about future cardiovascular risk, the role of oxytocin as a confounder must be determined. In
      the current study, we aim to determine whether oxytocin, physiologically produced during
      breastfeeding, has an effect on the UtA Doppler measurements in the postpartum period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Postpartum uterine artery doppler changes prior and after breastfeeding.</measure>
    <time_frame>One year</time_frame>
    <description>To determine whether there are any differences in the UtA doppler measurements in postpartum women prior and right after breastfeeding.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Breastfeeding</condition>
  <arm_group>
    <arm_group_label>Prior to breastfeeding - cross section</arm_group_label>
    <description>Measurements of the UtA doppler postpartum ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>After breastfeeding - cross section</arm_group_label>
    <description>Measurements of the UtA doppler postpartum ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Postpartum ultrasound</intervention_name>
    <description>Measurements of the UtA doppler ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.</description>
    <arm_group_label>After breastfeeding - cross section</arm_group_label>
    <arm_group_label>Prior to breastfeeding - cross section</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Every woman who had vaginal delivery, instrumental delivery or cesarean section.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Every woman who had vaginal delivery, instrumental delivery or cesarean section.

        Exclusion Criteria:

        -Patient's refusal, women who decided not to breastfeed, women who wish to breastfeed, but
        in whom no milk production commenced yet.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postpartum women</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaniv Zipori, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yaniv Zipori, M.D</last_name>
    <phone>+972 58 7966963</phone>
    <email>y_zipori@rambam.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam health care campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaniv Zipori, MD</last_name>
      <phone>0587966963</phone>
      <email>y_zipori@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2018</study_first_posted>
  <last_update_submitted>December 25, 2018</last_update_submitted>
  <last_update_submitted_qc>December 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Yaniv Zipori MD</investigator_full_name>
    <investigator_title>Doctor Yaniv Zipori</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

